Journal of Thrombosis and Thrombolysis

, Volume 29, Issue 3, pp 368–377 | Cite as

Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician

  • Anandi Krishnan
  • Renato D. Lopes
  • John H. Alexander
  • Richard C. Becker
  • Larry B. Goldstein
Article

Abstract

Acute ischemic stroke is the result of abrupt interruption of focal cerebral blood flow. The majority of ischemic strokes are caused by embolic or thrombotic arterial occlusions. Acute stroke management is complex, in part because of the varying etiologies of stroke and the very brief window of time for reperfusion therapy. Efforts to optimize stroke care have also encountered barriers including low public awareness of stroke symptoms. As initiatives move forward to improve stroke care worldwide, health care providers and institutions are being called onto deliver the most current evidence-based care. Updated versions of three major guidelines were published in 2008 by the American College of Chest Physicians, the American Heart Association, and the European Stroke Organization. This article presents a concise overview of current recommendations for the use of fibrinolytic therapy for acute ischemic stroke and antithrombotic therapy for secondary prevention. Future directions are also reviewed, with particular emphasis on improving therapeutic options early after stroke onset.

Keywords

Antithrombotic therapy Ischemic stroke Guidelines 

References

  1. 1.
    Broderick JP (2004) William M. Feinberg Lecture: stroke therapy in the year 2025: burden, breakthroughs, and barriers to progress. Stroke 35:205–211CrossRefPubMedGoogle Scholar
  2. 2.
    Brown DL, Boden-Albala B, Langa KM et al (2006) Projected costs of ischemic stroke in the United States. Neurology 67:1390–1395CrossRefPubMedGoogle Scholar
  3. 3.
    Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P (2008) Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:630S–669SCrossRefPubMedGoogle Scholar
  4. 4.
    Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P (2004) Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:483S–512SCrossRefPubMedGoogle Scholar
  5. 5.
    Akhtar RP, Abid AR, Zafar H, Khan JS (2009) Anticoagulation in patients following prosthetic heart valve replacement. Ann Thorac Cardiovasc Surg 15:10–17PubMedGoogle Scholar
  6. 6.
    Adams RJ, Albers G, Alberts MJ et al (2008) Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39:1647–1652CrossRefPubMedGoogle Scholar
  7. 7.
    Kang C, Schneck M (2004) The role of guidelines in stroke. Semin Cerebrovasc Dis Stroke 4:155–158CrossRefGoogle Scholar
  8. 8.
    European Stroke Organisation Executive Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507CrossRefGoogle Scholar
  9. 9.
    Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest 129:174–181CrossRefPubMedGoogle Scholar
  10. 10.
    Panagos PD (2008) The approach to optimizing stroke care. Am J Emerg Med 26:808–816CrossRefPubMedGoogle Scholar
  11. 11.
    Hart RG, Boop BS, Anderson DC (1995) Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 26:1471–1477PubMedGoogle Scholar
  12. 12.
    Lyden P (2008) Thrombolytic therapy for acute stroke—not a moment to lose. N Engl J Med 359:1393–1395CrossRefPubMedGoogle Scholar
  13. 13.
    Hacke W, Brott T, Caplan L et al (1999) Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53:S3–S14PubMedGoogle Scholar
  14. 14.
    Marler JR, Tilley BC, Lu M et al (2000) Early stroke treatment associated with better outcome: the NINDS rt-Pa stroke study. Neurology 55:1649–1655PubMedGoogle Scholar
  15. 15.
    Hacke W, Ringleb P, Stingele R (1999) How did the results of ECASS II influence clinical practice of treatment of acute stroke. Rev Neurol 29:638–641PubMedGoogle Scholar
  16. 16.
    Brott T, Bogousslavsky J (2000) Treatment of acute ischemic stroke. N Engl J Med 343:710–722CrossRefPubMedGoogle Scholar
  17. 17.
    del Zoppo GJ, Saver JL, Jauch EC et al (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40:2945–2948CrossRefPubMedGoogle Scholar
  18. 18.
    Chen ZM, Sandercock P, Pan HC et al (2000) Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31:1240–1249PubMedGoogle Scholar
  19. 19.
    The International Stroke Trial (1997) A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569–1581CrossRefGoogle Scholar
  20. 20.
    Cerebral Embolism Study Group (1983) Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 14:668–676Google Scholar
  21. 21.
    Cerebral Embolism Study Group (1984) Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke 15:779–789Google Scholar
  22. 22.
    Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329CrossRefPubMedGoogle Scholar
  23. 23.
    Sandercock PA, Counsell C, Gubitz GJ, Tseng MC et al. (2008) Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev CD000029 (3)Google Scholar
  24. 24.
    Sandercock PA, Counsell C, Kamal AK (2008) Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev CD000024 (4)Google Scholar
  25. 25.
    Sandercock PA, Counsell C, Tseng MC (2008) Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev CD000119 (3)Google Scholar
  26. 26.
    Haas S (2001) Prevention of venous thromboembolism: recommendations based on the International Consensus and the American College of Chest Physicians Sixth Consensus Conference on Antithrombotic Therapy. Clin Appl Thromb Hemost 7:171–177CrossRefPubMedGoogle Scholar
  27. 27.
    Kase CS, Pineo GF (2008) Prevention of venous thromboembolism after ischemic stroke. Curr Opin Pulm Med 14:389–396CrossRefPubMedGoogle Scholar
  28. 28.
    Coull AJ, Lovett JK, Rothwell PM (2004) Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328:326CrossRefPubMedGoogle Scholar
  29. 29.
    Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO (1998) Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50:208–216PubMedGoogle Scholar
  30. 30.
    Graham GD (2008) Secondary stroke prevention: from guidelines to clinical practice. J Natl Med Assoc 100:1125–1137PubMedGoogle Scholar
  31. 31.
    Hankey GJ, Warlow CP (2000) Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 355:320–321CrossRefGoogle Scholar
  32. 32.
    Bushnell C, Zimmer L, Schwamm L et al (2009) The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: design, rationale, and baseline patient characteristics. Am Heart J 157:428–435CrossRefPubMedGoogle Scholar
  33. 33.
    Stoeckle-Roberts S, Reeves MJ, Jacobs BS et al (2006) Closing gaps between evidence-based stroke care guidelines and practices with a collaborative quality improvement project. Jt Comm J Qual Patient Saf 32:517–527PubMedGoogle Scholar
  34. 34.
    Schwamm LH, Fonarow GC, Reeves MJ et al (2009) Get with the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119:107–115CrossRefPubMedGoogle Scholar
  35. 35.
    LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm L (2008) Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “Get with the Guidelines” program. Arch Intern Med 168:411–417CrossRefPubMedGoogle Scholar
  36. 36.
    Grotta JC (1999) Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside. The Feinberg lecture. Stroke 30:1722–1728PubMedGoogle Scholar
  37. 37.
    Liebeskind DS (2009) Reversing stroke in the 2010s: lessons from Desmoteplase in Acute Ischemic Stroke-2 (DIAS-2). Stroke 40:315–318CrossRefGoogle Scholar
  38. 38.
    Johnston SC (2008) The 2008 William M. Feinberg lecture: prioritizing stroke research. Stroke 39:3431–3436CrossRefPubMedGoogle Scholar
  39. 39.
    Turley KR, Toledo-Pereyra LH, Kothari RU (2005) Molecular mechanisms in the pathogenesis and treatment of acute ischemic stroke. J Invest Surg 18:207–218CrossRefPubMedGoogle Scholar
  40. 40.
    Adkins DL, Schallert T, Goldstein LB (2009) Poststroke treatment: lost in translation. Stroke 40:8–9CrossRefPubMedGoogle Scholar
  41. 41.
    Wardlaw JM (2001) Overview of Cochrane thrombolysis meta-analysis. Neurology 57:S69–S76PubMedGoogle Scholar
  42. 42.
    Ingall TJ (2009) Intravenous thrombolysis for acute ischemic stroke: time is prime. Stroke 40:2264–2265CrossRefPubMedGoogle Scholar
  43. 43.
    Aronowski J, Ostrow P, Samways E, Strong R, Zivin JA, Grotta JC (1994) Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke 25:2235–2240PubMedGoogle Scholar
  44. 44.
    Aronowski J, Strong R, Grotta JC (1997) Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 17:1048–1056CrossRefPubMedGoogle Scholar
  45. 45.
    Hacke W, Furlan AJ, Al-Rawi Y et al (2009) Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 8:141–150CrossRefPubMedGoogle Scholar
  46. 46.
    Study of the combination therapy of Rt-Pa and eptifibatide to treat acute ischemic stroke (CLEAR-ER Stroke Trial). Clinical Trials.gov Identifier NCT00894803. Available at http://www.clinicaltrials.gov/ct2/show/NCT00894803?term=NCT00894803&rank=1. Accessed 4 December 2009
  47. 47.
    Adjunctive drug treatment for ischemic stroke patients. Clinical Trials.gov Identifier NCT00061373. Available at http://www.clinicaltrials.gov/ct2/show/NCT00061373?term=nct00061373&rank=1. Accessed 4 December 2009
  48. 48.
    Enoxaparin and/or minocycline in acute stroke. Clinical Trials.gov Identifier NCT00836355. Available at http://www.clinicaltrials.gov/ct2/show/NCT00836355?term=nct00836355&rank=1. Accessed 4 December 2009
  49. 49.
    Lohrmann J, Becker RC (2008) New anticoagulants—the path from discovery to clinical practice. N Engl J Med 358:2827–2829CrossRefPubMedGoogle Scholar
  50. 50.
    Harrington RA (2003) Developing drugs to prevent and treat arterial thrombosis. Available at http://www.cardiologyrounds.org/crus/cardious_0809.pdf. Accessed 4 December 2009
  51. 51.
    Coull BM, Williams LS, Goldstein LB et al (2002) Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Neurology 59:13–22PubMedGoogle Scholar
  52. 52.
    Becker RC, Rusconi C, Sullenger B (2005) Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 93:1014–1020PubMedGoogle Scholar
  53. 53.
    Becker RC, Oney S, Becker KC, Rusconi CP, Sullenger B (2007) Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. Hamostaseologie 27:378–382PubMedGoogle Scholar
  54. 54.
    Becker RC (2007) Emerging paradigms, platforms, and unifying themes in biomarker science. J Am Coll Cardiol 50:1777–1780CrossRefPubMedGoogle Scholar
  55. 55.
    Rusconi CP, Roberts JD, Pitoc GA et al (2004) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22:1423–1428CrossRefPubMedGoogle Scholar
  56. 56.
    Rusconi CP, Scardino E, Layzer J et al (2002) RNA aptamers as reversible antagonists of coagulation factor Ixa. Nature 419:90–94CrossRefPubMedGoogle Scholar
  57. 57.
    Oney S, Nimjee SM, Layzer J et al (2007) Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17:265–274CrossRefPubMedGoogle Scholar
  58. 58.
    Chan MY, Cohen MG, Dyke CK et al (2008) Phase 1b randomized study of antidote-controlled modulation of factor Ixa activity in patients with stable coronary artery disease. Circulation 117:2865–2874CrossRefPubMedGoogle Scholar
  59. 59.
    Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC (2008) A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor Ixa inhibitor. J Thromb Haemost 6:789–796CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Anandi Krishnan
    • 1
  • Renato D. Lopes
    • 1
  • John H. Alexander
    • 1
  • Richard C. Becker
    • 1
  • Larry B. Goldstein
    • 2
  1. 1.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA
  2. 2.Division of Neurology, Department of MedicineDuke University Medical CenterDurhamUSA

Personalised recommendations